Price competition’s society-altering test Illustration: Aïda Amer/Axios Two facts about GLP-1s tend to dominate conversations: Their effectiveness is almost too good to be true, and if everyone who could benefit from them received them — at least at current prices — the cost would be prohibitively expensive. Why it matters: With the development pipeline chock-full...
